Merck's Plan for Relief
After a mistrial in the first federal Vioxx case, the drugmaker turns its attention to cutting costs. Will it be enough to please investors?
By Amy Barrett
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: